Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) PT at $6.00

Posted by on Aug 14th, 2023

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) have received an average recommendation of “Buy” from the four brokerages that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $6.00.

CLSD has been the topic of a number of research reports. 500.com reissued a “reiterates” rating on shares of Clearside Biomedical in a report on Friday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 price objective on shares of Clearside Biomedical in a research report on Thursday, April 20th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a report on Wednesday, April 19th. Finally, StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 17th.

View Our Latest Research Report on Clearside Biomedical

Institutional Trading of Clearside Biomedical

A number of hedge funds and other institutional investors have recently modified their holdings of CLSD. Northeast Financial Consultants Inc boosted its position in shares of Clearside Biomedical by 56.6% during the fourth quarter. Northeast Financial Consultants Inc now owns 83,000 shares of the company’s stock worth $93,000 after buying an additional 30,000 shares during the period. Water Island Capital LLC acquired a new position in shares of Clearside Biomedical during the 4th quarter valued at about $53,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Clearside Biomedical during the 2nd quarter worth about $35,000. Virtu Financial LLC bought a new position in Clearside Biomedical during the second quarter valued at about $38,000. Finally, Stratos Wealth Partners LTD. increased its holdings in Clearside Biomedical by 56.6% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 39,442 shares of the company’s stock valued at $44,000 after buying an additional 14,262 shares during the period. 14.18% of the stock is owned by hedge funds and other institutional investors.

Clearside Biomedical Trading Down 3.7 %

Shares of Clearside Biomedical stock opened at $1.05 on Friday. Clearside Biomedical has a 12 month low of $0.90 and a 12 month high of $1.85. The stock has a 50 day moving average of $1.20 and a 200 day moving average of $1.17. The firm has a market cap of $64.75 million, a PE ratio of -1.84 and a beta of 2.09.

Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last issued its earnings results on Thursday, May 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Clearside Biomedical had a negative return on equity of 242.26% and a negative net margin of 3,514.53%. As a group, equities research analysts forecast that Clearside Biomedical will post -0.59 earnings per share for the current fiscal year.

About Clearside Biomedical

(Get Free Report

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Further Reading

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.